Global Atrial Fibrillation
Market Report
2025
Global Atrial Fibrillation Market size is USD 10584.2 million in 2024. The aging population, lifestyle changes, and the surge in chronic illnesses such as obesity and diabetes are expected to boost sales to USD 16447.7 Million by 2031 with a Compound Annual Growth Rate (CAGR) of 6.50% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Atrial Fibrillation Market Report 2024.
According to Cognitive Market Research, the global Atrial Fibrillation market size will be USD 10584.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Atrial Fibrillation Market Sales Revenue 2020 | $ 1801.57 Million |
Global Atrial Fibrillation Market Sales Revenue 2030 | $ 3200.16 Million |
Global Atrial Fibrillation Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 6.59% |
Market Drivers:
| |
Market Restrains:
|
Market Split by Type |
|
Market Split by Technology |
|
Market Split by End-user |
|
Market Split by Conclusion | |
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Atrial Fibrillation industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Atrial Fibrillation Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Atrial fibrillation (AF) is the most common arrhythmia, caused by irregular electrical impulses reaching the heart's upper chambers (atria), leading to a rapid and erratic heart rhythm of 100 to 175 beats per minute. This disorder often results in confusion, fatigue, dizziness, and fainting. Treating AF is considered strategically important in the healthcare system due to its potentially fatal nature and high treatment costs. A significant factor expected to drive the global atrial fibrillation market during the forecast period is the increasing elderly population worldwide. As the risk of AF is higher among older individuals, this demographic shift is contributing to the market's expansion.
For instance, In January 2022, Voluntis, a leading digital therapeutics company under Aptar Pharma, entered into a partnership with AliveCor, Inc. to advance the management of atrial fibrillation in cancer patients. (Source: https://aptar.com/wp-content/uploads/2022/01/PR-January-6-2022-Voluntis-AliveCor-Partnership-Announcement.pdf )
The increasing elderly population is a key driver in the atrial fibrillation market, given their heightened susceptibility to the condition. By 2030, the World Health Organization (WHO) predicts that one in every six individuals globally will be aged 60 or above, signaling a notable demographic shift. Over this period, the proportion of this age group is expected to grow from 1 billion in 2020 to 1.4 billion. Looking further ahead to 2050, the worldwide population of individuals aged 60 and older is forecasted to double, reaching 2.1 billion. Moreover, there is an anticipated threefold rise in the number of those aged 80 years or older between 2020 and 2050, totaling 426 million. These demographic projections highlight the significant aging trend that will shape the population in the forthcoming decades.
Atrial fibrillation frequently occurs alongside other cardiovascular conditions like hypertension, coronary artery disease, and heart failure. Cardiovascular diseases (CVDs) stand as the primary cause of global mortality, claiming an estimated 17.9 million lives annually. In 2020 alone, around 19.1 million deaths were linked to CVDs worldwide. The age-adjusted death rate per 100,000 population was 239.8, while the age-adjusted prevalence rate stood at 7354.1 per 100,000. It was estimated globally that 244.1 million individuals were living with ischemic heart disease (IHD) in 2020, with a higher prevalence observed in males compared to females (141.0 million versus 103.1 million). The escalating incidence and prevalence of these concurrent conditions contribute significantly to the increasing burden of atrial fibrillation worldwide. As awareness surrounding cardiovascular health improves and diagnostic methods become more advanced, there's a rise in the detection of AF cases, thereby propelling market growth.
Treating atrial fibrillation, particularly with advanced methods like catheter ablation and implantable device therapy, can be costly. The significant expense associated with these procedures and devices might create financial hurdles for certain patients, especially in areas with limited healthcare resources or insufficient insurance coverage. Cost-related concerns may prompt patients to choose conservative management approaches or postpone seeking treatment, potentially hindering the expansion of the AF market.
Amid the pandemic, healthcare systems encountered considerable strain due to the surge in COVID-19 cases, resulting in disruptions to routine medical services, including the diagnosis and management of AF. Elective procedures like catheter ablation for AF were frequently postponed or canceled to allocate resources to COVID-19 patients, causing treatment delays and decreased procedural volumes. Access to diagnostic tests such as electrocardiography (ECG) and Holter monitoring may have been restricted, leading to potential underdiagnosis or delayed diagnosis of AF. Additionally, routine screening programs and preventive care initiatives for AF might have been deprioritized or temporarily halted, possibly impacting the identification of new cases.
We have various report editions of Atrial Fibrillation Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The competitive landscape of the Atrial Fibrillation market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established manufacturers, specialized Atrial Fibrillation companies, and emerging start-ups aiming to disrupt the market with innovative solutions.
September 2019: iRhythm Technologies, Inc. announced a collaboration with Verily, an Alphabet company, to develop solutions aimed at improving the screening, diagnosis, and management of atrial fibrillation (AFib) patients. (Source: https://www.irhythmtech.com/company/press-releases/irhythm-announces-collaboration-with-verily-to-develop-health-management-solutions-for-atrial-fibrillation-patients#:~:text=SAN%20FRANCISCO%2C%20September%204%2C%202019,with%20atrial%20fibrillation%20(AFib). )
Top Companies Market Share in Atrial Fibrillation Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. North America, particularly the United States, experiences a high prevalence of atrial fibrillation and other cardiovascular diseases. Contributing factors include an aging population, sedentary lifestyles, high obesity rates, and widespread conditions such as hypertension and diabetes. The number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, a 47% increase, with this age group’s share of the total population rising from 17% to 23%. In 2021, among U.S. adults aged 18 years or older, 97.6 million—more than one in three—had prediabetes. This includes 32.8 million adults aged 18 to 44, 37.5 million adults aged 45 to 64, and 27.2 million adults aged 65 or older. This large patient population drives the demand for AF-related treatments and services.
Asia Pacific stands out as the fastest-growing region in the Atrial Fibrillation market due to several compelling reasons. ? The prevalence of atrial fibrillation is rising in the Asia Pacific region, primarily due to an aging population and the increasing burden of cardiovascular diseases. Countries such as China, Japan, and India have substantial elderly populations that are more prone to AF. According to a report by the United Nations Population Fund and the International Institute for Population Sciences, India's elderly population is expected to double to 20.8% by 2050 and reach 36% by the end of the century. This demographic shift towards an older population significantly contributes to the growing incidence of AF in the region.
The current report Scope analyzes Atrial Fibrillation Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 4233.6 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 3175.2 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 2434.3 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 529.2 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 211.6 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Global Atrial Fibrillation Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Atrial Fibrillation Industry growth. Atrial Fibrillation market has been segmented with the help of its Type, Technology End-user, and others. Atrial Fibrillation market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
According to Cognitive Market Research, Surgical type stands out as the dominating category. Surgical interventions for atrial fibrillation, including catheter ablation and maze procedures, have demonstrated high success rates in restoring normal heart rhythm and preventing AF recurrence. These procedures are often more effective than pharmacological treatments, especially in patients with persistent or long-standing persistent AF. This superior efficacy drives the demand and market dominance of surgical treatments.
Pharmacological Drugs emerge as the fastest-growing category in the Atrial Fibrillation market. Pharmacological drugs are typically the first-line treatment for atrial fibrillation. Medications such as anticoagulants, antiarrhythmics, beta-blockers, and calcium channel blockers are prescribed to manage heart rate, maintain sinus rhythm, and prevent thromboembolic events. The widespread initial use of these drugs significantly contributes to their dominance in the market.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Atrial Fibrillation Industry. Request a Free Sample PDF!
According to Cognitive Market Research, the dominating technology is Radiofrequency. Radiofrequency ablation is extensively researched and clinically validated as an effective treatment for atrial fibrillation. This procedure entails delivering controlled radiofrequency energy to targeted areas of the heart, resulting in the formation of scar tissue that interrupts abnormal electrical pathways causing AF. Multiple studies have consistently reported high success rates in restoring sinus rhythm and reducing AF recurrence with radiofrequency ablation, establishing it as the preferred option for many patients and healthcare providers.
The fastest-growing technology in the Atrial Fibrillation market is Cryotherapy. Cryotherapy, particularly cryoablation, has demonstrated notable safety and efficacy in managing atrial fibrillation. Cryoablation employs extreme cold temperatures to create scar tissue and disrupt irregular electrical pathways in the heart. Clinical investigations have affirmed that cryoablation effectively restores normal heart rhythm while minimizing the occurrence of complications. Consequently, cryoablation is favored by both patients and healthcare providers as an alternative treatment option for atrial fibrillation.
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
According to Cognitive Market Research, the dominating End user is Hospitals. Hospitals are equipped with sophisticated medical infrastructure, including specialized electrophysiology labs that feature cutting-edge cardiac mapping systems, ablation catheters, and monitoring devices. This infrastructure enables hospitals to provide a comprehensive array of diagnostic and treatment services for atrial fibrillation (AF), ranging from catheter ablation to surgical interventions and implantable device therapies. The availability of advanced equipment and facilities positions hospitals as the preferred choice for managing complex AF cases.
The fastest-growing End user in the Atrial Fibrillation market is Specialty Clinics. Specialty clinics, focusing solely on cardiology or electrophysiology, boast a heightened level of expertise and specialization in AF management compared to general healthcare facilities. Cardiologists and electrophysiologists at these clinics possess extensive training and hands-on experience in diagnosing and treating arrhythmias, including AF. Their specialized knowledge enables them to deliver personalized and thorough care to patients with AF, ensuring optimal treatment outcomes.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Disclaimer:
Type | Surgical, Non-Surgical, Pharmacological Drugs |
Technology | Radiofrequency, Laser, Cryotherapy, Others |
End-user | Hospitals, Specialty Clinics, Others |
Conclusion | |
List of Competitors | Abbott (US), Johnson & Johnson Private Limited (U.S.), MicroPort Scientific Corporation. (China), Boston Scientific Corporation (US)., Medtronic (US), BIOTRONIK SE & Co. KG (US), Koninklijke Philips N.V. (Netherlands), Siemens (US), AtriCure, Inc (US), Sanofi (US), Biosense Webster, Inc (US), CardioFocus. (US), BRISTOL-MYERS SQUIBB COMPANY (US), Boehringer Ingelheim International GmbH. (US), GENERAL ELECTRIC COMPANY (US), Pfizer Inc. (US) |
This chapter will help you gain GLOBAL Market Analysis of Atrial Fibrillation. Further deep in this chapter, you will be able to review Global Atrial Fibrillation Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
This chapter will help you gain North America Market Analysis of Atrial Fibrillation. Further deep in this chapter, you will be able to review North America Atrial Fibrillation Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
This chapter will help you gain Europe Market Analysis of Atrial Fibrillation. Further deep in this chapter, you will be able to review Europe Atrial Fibrillation Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
This chapter will help you gain Asia Pacific Market Analysis of Atrial Fibrillation. Further deep in this chapter, you will be able to review Asia Pacific Atrial Fibrillation Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
This chapter will help you gain South America Market Analysis of Atrial Fibrillation. Further deep in this chapter, you will be able to review South America Atrial Fibrillation Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
This chapter will help you gain Middle East and Africa Market Analysis of Atrial Fibrillation. Further deep in this chapter, you will be able to review Middle East and Africa Atrial Fibrillation Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
This chapter provides an in-depth analysis of the market share among key competitors of Atrial Fibrillation. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Technology Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End-user Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Conclusion Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Atrial Fibrillation market
Chapter 14 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Surgical have a significant impact on Atrial Fibrillation market? |
What are the key factors affecting the Surgical and Non-Surgical of Atrial Fibrillation Market? |
What is the CAGR/Growth Rate of Radiofrequency during the forecast period? |
By type, which segment accounted for largest share of the global Atrial Fibrillation Market? |
Which region is expected to dominate the global Atrial Fibrillation Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Atrial Fibrillation Market
Request Sample